Global Health & Human Rights

  • Read more: Transplant Tourism: Hard Questions Posed by the International and Illicit Market for Kidneys, New Article I Wrote

    Transplant Tourism: Hard Questions Posed by the International and Illicit Market for Kidneys, New Article I Wrote

    By I. Glenn Cohen [Cross-Posted at Prawfsblawg] The Journal of Law, Medicine, and Ethics has just published an article by me on transplant tourism, that discusses the burgeoning international market for buying and selling kidneys. I review the existing data from Pakistan, Bangladesh, and India, which is pretty deplorable. As I show the vast majority…

  • Read more: 4/25: Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies

    4/25: Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies

    By Adriana Benedict Universities Allied for Essential Medicines (UAEM)Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies Thursday, April 25th, 3-5pmCoffee and refreshments at 2:45pm; reception following the eventHarvard Medical School New Research Building – 77 Avenue Louis PasteurSeminar Room 1031 How do innovative medical technologies make their way to a global population, including…

  • Read more: Of Evergreening and Efficacy, Part III

    Of Evergreening and Efficacy, Part III

    By Ryan Abbott This is the last in a three-part series (Part I, Part II) of posts I’ve written about the case between Novartis and the Union of India, in which the Supreme Court of India denied Novartis a patent for its anti-cancer drug Glivec. Today I’m continuing the discussion of the practical outcome of the case.…

  • Read more: Of Evergreening and Efficacy, Part II

    Of Evergreening and Efficacy, Part II

    By Ryan Abbott I wrote earlier this month about the case between Novartis and the Union of India, in which the Supreme Court of India affirmed denying a patent for Novartis’ anti-cancer drug Glivec. Adriana Benedict added an insightful post about the case last week. In my last post, I talked about the theory behind the decision and…

  • Read more: If Novartis’s “improved” version of Glivec is not more therapeutically efficacious, why is the Novartis decision such a big deal?

    If Novartis’s “improved” version of Glivec is not more therapeutically efficacious, why is the Novartis decision such a big deal?

    By Adriana Benedict Last week, Ryan Abbot blogged here about the Novartis case decided last Monday by the Supreme Court of India.  Since then, there have been a broad range of reactions to the case, but many of them appear to have left a lurking elephant in the room. I’d like to attempt to provide…

  • Read more: More on the M&M Study

    More on the M&M Study

    By Scott Burris Stephanie Morain and Michelle Mello’s recent paper in the March issue of Health Affairs is an extremely important contribution. It reports on a survey of American adults investigating their support for a range of current health interventions, and finds – contrary to the myth being propagated in politics and the media –…

  • Read more: Of Evergreening and Efficacy

    Of Evergreening and Efficacy

    By Ryan Abbott An important case was decided yesterday that may have a significant impact on access to medicines for patients in developing countries. India’s high court rejected an appeal by the pharmaceutical company Novartis to grant a patent for its cancer drug Glivec. The case involved a challenge to Section 3(d) of the Indian…

  • Read more: The Iraq War and Health Worker Brain Drain

    The Iraq War and Health Worker Brain Drain

    By Yoni Schenker I am writing my student fellowship paper under the broad topic of health worker “brain drain,” so I have been keeping an eye out for related news stories.  Two stories that caught my eye in the past few weeks were about the health worker migration from civil war torn Syria and economic-crisis…

  • Read more: Reminder, Upcoming Conference on Universal Health Coverage in Low-Income Countries

    Reminder, Upcoming Conference on Universal Health Coverage in Low-Income Countries

    By The Petrie-Flom Center A reminder that the Harvard University Program in Ethics and Health annual conference, Universal Health Coverage in Low-Income Countries: Ethical Issues, will be held in Boston on April 18-19, 2013. AGENDA https://peh.harvard.edu/events/2013/universal_coverage/agenda.html REGISTRATION No fee. Space limited. Registration required. Please register on our registration website.